10-QPeriod: Q3 FY2012

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2012

Filed October 19, 2012For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported solid financial results for the nine months ended September 30, 2012, with total revenue increasing by 6.8% to $973.8 million. The Companion Animal Group (CAG) remains the largest segment, driving growth with an 8.1% revenue increase year-over-year, primarily due to strong performance in reference laboratory diagnostics and consulting services, as well as rapid assay products. The company's financial position remains robust, with cash and cash equivalents increasing to $221.4 million and a healthy working capital of $154.9 million. Management expects these resources, along with its credit facility, to be sufficient to fund operations and strategic growth initiatives. The company is actively managing potential regulatory and legal challenges, notably the ongoing FTC investigation into its marketing and sales practices. IDEXX has taken proactive steps, including modifying an agreement with a key distributor, to address concerns and is negotiating a consent order. While the outcome remains uncertain, management believes these actions will mitigate material adverse effects on financial statements. The company continues to prioritize innovation and market expansion across its segments, including veterinary diagnostics, water quality, and livestock/poultry health, while navigating economic uncertainties and foreign currency fluctuations.

Financial Highlights

50 data points
Beta

Revenue

$315.48M

54.1% Gross Margin

Net Income

$42.85M

13.6% Net Margin

EPS (Diluted)

$0.38

Total Assets

$1.09B

Cash & Equivalents

$221.44M

Free Cash Flow

$55.76M

Financial Statements
Beta
Revenue$315.48M
Cost of Revenue$144.84M
Gross Profit$170.63M
R&D Expenses$20.35M
Operating Income$62.91M
Interest Expense$873K
Net Income$42.85M
EPS (Basic)$0.39
EPS (Diluted)$0.38
Shares Outstanding (Basic)109.88M
Shares Outstanding (Diluted)112.18M

Key Highlights

  • 1Total revenue for the nine months ended September 30, 2012, increased by 6.8% to $973.8 million, compared to $911.5 million in the prior year period.
  • 2The Companion Animal Group (CAG) continues to be the primary revenue driver, with an 8.1% increase in revenue year-over-year, reaching $808.7 million for the nine months.
  • 3Net income attributable to IDEXX Laboratories, Inc. stockholders rose to $134.9 million for the nine months ended September 30, 2012, up from $123.8 million in the prior year.
  • 4Diluted earnings per share increased to $2.40 for the nine months ended September 30, 2012, from $2.11 in the comparable prior year period.
  • 5Cash and cash equivalents increased to $221.4 million at September 30, 2012, from $183.9 million at December 31, 2011, indicating strong liquidity.
  • 6The company reported $153.5 million in cash flow from operating activities for the nine months ended September 30, 2012, slightly down from $163.5 million in the prior year, reflecting changes in working capital.
  • 7IDEXX is actively engaged in discussions and negotiations with the FTC regarding an investigation into its marketing and sales practices, with efforts underway to reach a resolution.

Frequently Asked Questions

For the nine months ended September 30, 2012, IDEXX Laboratories reported a total revenue of $973.8 million, representing a 6.8% increase compared to $911.5 million in the same period of the prior year. This growth was primarily driven by the Companion Animal Group (CAG) segment.

The Companion Animal Group (CAG) demonstrated strong performance, with revenue increasing by 8.1% year-over-year to $808.7 million for the first nine months of 2012. Key growth drivers include reference laboratory diagnostic and consulting services, rapid assay products, and instruments and consumables, reflecting continued demand in the veterinary market.

IDEXX Laboratories maintained a strong liquidity position, with cash and cash equivalents totaling $221.4 million at September 30, 2012, an increase from $183.9 million at December 31, 2011. The company also had $67 million in remaining borrowing availability under its credit facility. Management believes these resources are sufficient to fund operations, capital expenditures, and strategic growth initiatives for the next twelve months and beyond.

IDEXX is currently involved in an investigation by the U.S. Federal Trade Commission (FTC) concerning its marketing and sales practices for companion animal veterinary products and services. The company has taken steps to address the FTC's concerns, including modifying an agreement with a distributor and negotiating a consent order. While the resolution is uncertain, management believes that these actions and ongoing negotiations are likely to mitigate any material adverse effects on the company's financial statements.